117348-08-0

Basic information

• Product Name: {2-[1-(3-Methoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine
• Synonyms: {2-[1-(3-Methoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine
• CAS NO: 117348-08-0
• Molecular Weight: 340.449
• Mol File: 117348-08-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: {2-[1-(3-Methoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: {2-[1-(3-Methoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine(117348-08-0)
• EPA Substance Registry System: {2-[1-(3-Methoxy-pyridin-2-yl)-1H-imidazol-2-ylsulfanylmethyl]-phenyl}-dimethyl-amine(117348-08-0)

Safety Data

• Hazardous Substances Data: 117348-08-0(Hazardous Substances Data)

Upstream product

• 106771-59-9 2-(chloromethyl)-N,N-dimethylaniline 
• 117296-71-6 1-(3-Methoxy-pyridin-2-yl)-1,3-dihydro-imidazole-2-thione 
• 4707-56-6 (2-(dimethylamino)phenyl)methanol 
• 1027925-75-2 1-(2,2-Diethoxy-ethyl)-3-(3-methoxy-pyridin-2-yl)-thiourea 
• 10072-05-6 methyl 2-(dimethylamino)benzoate 
• 394-35-4 methyl 2-fluorobenzoate 
• 10201-71-5 3-methoxypyridin-2-amine 

Relevant articles and documents

2-[(2-Aminobenzyl)sulfinyl]-1-(2-pyridyl)-1,4,5,6- tetrahydrocyclopent[d]imidazoles as a novel class of gastric H+/K+-ATPase inhibitors

Substituted 2-sulfinylimidazoles were synthesized and investigated as potential inhibitors of gastric H+/K+-ATPase. The 4,5-unsubstituted imidazole series 6-11 and the 1,4,5,6-tetrahydrocyclopent[d]imidazole series 12 were found to be potent inhibitors of the acid secretory enzyme H+/K+- ATPase. Structure-activity relationships indicate that the substitution of 2- pyridyl groups at the 1-position of the imidazole moiety combined with (2- aminobenzyl)sulfinyl groups at the 2-position leads to highly active compounds with a favorable chemical stability. Other substitution patterns in the imidazole moiety result in reducing biological activities. 2-[(2- Aminobenzyl)sulfinyl]-1-[2-(3-methylpyridyl)]-1,4,5,6- tetrahydrocyclopent[d]imidazole (12h, T-776) was selected for further development as a potential clinical candidate. Extensive study on the acid degradation of 12h indicates a mechanism of action different from that of omeprazole, the first H+/K+-ATPase inhibitor introduced to the market.